The Development of Novel Hepatitis B Vaccines

Overview

Journal Bull World Health Organ

Specialty Public Health

Date 1987 Jan 1

PMID 2959387

Citations 4

Authors

A J Zuckerman

Affiliations

Soon will be listed here.

Abstract

Development of vaccines against viral hepatitis B has proceeded along four main lines. (1) Human plasma-derived vaccines are safe, effective and are now in general use. (2) Subunit polypeptide vaccines formulated in micelles have reached the stage of clinical trials. (3) Recombinant DNA vaccines have been produced in prokaryotic and eukaryotic cells, notably in yeast. The yeast-derived recombinant vaccines have proved safe and effective in extensive clinical trials, eliciting antibodies which in quantity and specificity are equal to those elicited by plasma-derived vaccine. DNA recombinant has also been applied to the development of hybrid and vaccinia virus vaccines which are capable of immunological "priming", and other hybrid virus vaccines are under development. (4) Finally, chemical synthesis has succeeded in producing small peptides which include specific epitopes eliciting antibody responses in experimental animals. Such chemically synthesized preparations offer a prospect of ultimately producing multivalent synthetic vaccines against several viruses, bacteria and protozoa.

Citing Articles

Prospects for vaccines against HIV.

Zuckerman A BMJ. 1988; 297(6641):86-8.

PMID: 3044502 PMC: 1833777. DOI: 10.1136/bmj.297.6641.86.

Immunoprophylaxis of hepatitis B in India.

Joshi Y Indian J Pediatr. 1988; 55(5):675-80.

PMID: 2977599 DOI: 10.1007/BF02734285.

Why clinical trials of AIDS vaccines are premature.

Mariner W Am J Public Health. 1989; 79(1):86-91.

PMID: 2642371 PMC: 1349480. DOI: 10.2105/ajph.79.1.86.

Epitope mapping of neutralizing monoclonal antibodies against duck hepatitis B virus.

Cheung R, ROBINSON W, Marion P, Greenberg H J Virol. 1989; 63(6):2445-51.

PMID: 2470915 PMC: 250697. DOI: 10.1128/JVI.63.6.2445-2451.1989.

References

Milich D, Thornton G, Neurath A, Kent S, Michel M, Tiollais P . Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985; 228(4704):1195-9. DOI: 10.1126/science.2408336. View

Hollinger F, Troisi C, Heiberg D, Sanchez Y, Dreesman G, Melnick J . Response to a hepatitis B polypeptide vaccine in micelle form in a young adult population. J Med Virol. 1986; 19(3):229-40. DOI: 10.1002/jmv.1890190305. View

Deinhardt F, Zuckerman A . Immunization against hepatitis B: report on a WHO meeting on viral hepatitis in Europe. J Med Virol. 1985; 17(3):209-17. DOI: 10.1002/jmv.1890170302. View

Tabor E, Howard C, Skelly J, Snoy P, Goudeau A, Zuckerman A . Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles. J Med Virol. 1982; 10(1):65-74. DOI: 10.1002/jmv.1890100109. View

Gerin J, Alexander H, Shih J, Purcell R, DApolito G, Engle R . Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. Proc Natl Acad Sci U S A. 1983; 80(8):2365-9. PMC: 393821. DOI: 10.1073/pnas.80.8.2365. View

Sanchez Y, Melnick J, Dreesman G . Comparative studies of the immunogenic activity of hepatitis B surface antigen (HBsAg) and HBsAg polypeptides. J Med Virol. 1983; 11(2):115-24. DOI: 10.1002/jmv.1890110205. View

Prince A, Ikram H, Hopp T . Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A. 1982; 79(2):579-82. PMC: 345788. DOI: 10.1073/pnas.79.2.579. View

Dreesman G, Sanchez Y, Sparrow J, Six H, Peterson D, Hollinger F . Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature. 1982; 295(5845):158-60. DOI: 10.1038/295158a0. View

Smith G, Mackett M, Moss B . Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature. 1983; 302(5908):490-5. DOI: 10.1038/302490a0. View

10.

. Health of Children in Wartime Day Nurseries. Br Med J. 2010; 2(4467):217-21. PMC: 2054176. View

11.

Neurath A, Kent S, Strick N, Parker K . Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell. 1986; 46(3):429-36. DOI: 10.1016/0092-8674(86)90663-x. View

12.

Lerner R, Green N, Alexander H, Liu F, Sutcliffe J, Shinnick T . Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc Natl Acad Sci U S A. 1981; 78(6):3403-7. PMC: 319576. DOI: 10.1073/pnas.78.6.3403. View

13.

Pabo C . Molecular technology. Designing proteins and peptides. Nature. 1983; 301(5897):200. DOI: 10.1038/301200a0. View

14.

Zuckerman A . New hepatitis B vaccines. Br Med J (Clin Res Ed). 1985; 290(6467):492-6. PMC: 1418009. DOI: 10.1136/bmj.290.6467.492. View

15.

Brown S, Howard C, Zuckerman A, Steward M . Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet. 1984; 2(8396):184-7. DOI: 10.1016/s0140-6736(84)90479-3. View

16.

Zuckerman A . Developing synthetic vaccines. Nature. 1982; 295(5845):98-9. DOI: 10.1038/295098a0. View

17.

Brown S, Howard C, Zuckerman A, Steward M . Determination of the affinity of antibodies to hepatitis B surface antigen in human sera. J Immunol Methods. 1984; 72(1):41-8. DOI: 10.1016/0022-1759(84)90431-9. View

18.

Neurath A, Kent S, Strick N, Stark D, Sproul P . Genetic restriction of immune responsiveness to synthetic peptides corresponding to sequences in the pre-S region of the hepatitis B virus (HBV) envelope gene. J Med Virol. 1985; 17(2):119-25. DOI: 10.1002/jmv.1890170204. View

19.

Rao K, VYAS G . Hepatitis B antigen activity in protein subunits produced by sonicaation. Nat New Biol. 1973; 241(112):240-1. DOI: 10.1038/newbio241240a0. View